Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:02:07.425Z.
Calculation as of: 2026-10-06T18:02:07.425Z.
Quote observation: 2026-10-06T17:04:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 787788ea5c712995087b0511470a3bc1500b131fb4a88c1f5ff44ca2612ce4c8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$51.23M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.39M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.42M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $52.05M | 2.64 | 2.45 | 5.29 | 4.64 |
| Clene Inc. (CLNN)vs › | $50.66M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.56M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $52.39M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $53.02M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.24M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute